PanGIA Biotech develops a non-invasive liquid biopsy platform utilizing urine specimens for early cancer detection. The core diagnostic system employs AI and machine learning to analyze biomolecular profiles, providing high sensitivity and specificity for various cancer types. This approach aims to improve diagnostic yield and reduce the need for invasive procedures like biopsies.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of cancer cases are diagnosed late each year, leading to decreased survival rates. Traditional cancer diagnostics often rely on invasive procedures like blood draws and biopsies, causing patient discomfort and limiting accessibility for frequent monitoring.
Solution
PanGIA Biotech offers a non-invasive liquid biopsy platform for early cancer detection, utilizing urine samples and AI-driven analysis. The platform analyzes biomolecular profiles in urine to identify cancer biomarkers, providing a simpler and less invasive alternative to traditional methods. By combining unbiased binding of molecules with machine learning algorithms, PanGIA aims to improve early detection rates, reduce the need for unnecessary biopsies, and enable more effective treatment strategies. The platform supports the development of non-invasive tests for various cancers, offering actionable insights for informed decision-making.
Target Audience
The primary target audience includes patients seeking early and non-invasive cancer detection methods, clinicians needing additional data points for identifying biopsy candidates, and payers aiming to avoid unnecessary biopsies and reduce healthcare costs.
Features
- Non-invasive cancer detection using urine samples, eliminating the need for blood draws or biopsies
- AI-powered analysis of biomolecular profiles for fast and actionable insights
- High sensitivity and specificity in detecting clinically significant cancers, as demonstrated by the PanGIA Prostate Assay
- Machine learning algorithms for interpreting complex data and extracting meaningful insights
- Support for early detection (Stages 1-2) when treatment is most effective
- Potential to reduce unnecessary biopsies, improve diagnostic yield, and lower healthcare costs
- Pipeline includes tests for prostate, breast, ovarian, lung, renal, bladder, colorectal, stomach, pancreas, liver, and brain cancers